Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia

被引:4
|
作者
Maiguma, T. [1 ]
Hayashi, Y. [2 ]
Ueshima, S. [2 ]
Kaji, H. [1 ]
Egawa, T. [1 ]
Chayama, K. [4 ]
Morishima, T. [4 ]
Kitamura, Y. [3 ]
Sendo, T. [2 ]
Gomita, Y. [1 ]
Teshima, D. [1 ]
机构
[1] Shujitsu Univ, Dept Clin Pharm, Sch Pharm, Okayama 7038516, Japan
[2] Okayama Univ Hosp, Dept Hosp Pharm, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharmaceut Sci, Okayama, Japan
[4] Okayama Univ Hosp, Dept Pediat, Okayama, Japan
关键词
high-dose methotrexate chemotherapy; pediatric acute lymphoblastic leukemia; oral mucositis; human epidermal keratinocytes; cell viability; pharmacokinetic parameters;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL). The first aim Of this Study was to evaluate the relationship between the MTX serum concentration and Occurrence of oral mucositis in pediatric ALL patients. The second aim was to clarify the relationship between MTX exposure and epidermal keratinocyte cell injury using an in vitro study. Methods: 49 patients were treated according to the Japan Association of Childhood Leukemia Study (JACLS) ALL-HR02 protocol. This protocol involves HD-MTX treatment (3 g/m(2) for 24-h i.v. infusion). The MTX serum concentrations were measured by a fluorescence polarization immunoassay. The relationship between oral mucositis and MTX serum concentrations 48 and 72 h after administration was determined. The cell toxicity or MTX for epidermal keratinocytes was analyzed by using a cell viability assay (WST-1 assay). In addition, pharmacokinetic evaluation for clearance, AUC extrapolated from 48 h to infinity (AUC(48h-infinity)) and elimination half-life 01,1210 were done using the 1-compartmental models. Results: Oral mucositis occurred in 24 patients (49.0%), in whom 20 patients (83.3% in oral mucositis group) showed WHO severity Grade 1 or 2. Only 4 patients (16.7% in oral mucositis group) showed Grade 3 severity. 22 patients (44.9%) had oral mucositis in the group With a concentration under 10(-6) M 48 h after MTX administration. There was no significant deference among the cell viabilities in the Concentrations of 10(-6) M, 10(-5) M and 10(-4) M 48 h after the MTX exposure. However, the cell viability obtained 24 h after the MTX exposure was significantly different from the respective cell viability 48, 72 and 96 h after the MTX exposure. In the group with oral mucositis, the clearance decreased significantly (p = 0.042), and the t(1/2 beta) (p = 0.025) and AUC(48h-infinity), (P = 0.025) increased significantly compared with the non-symptom group. Conclusions: It seems that there is no significant relationship between the serum MTX concentration and oral mucositis. This in vitro Study has demonstrated that the cell injury was related to the duration of MTX exposure rather than a high MTX concentration.
引用
收藏
页码:584 / 590
页数:7
相关论文
共 50 条
  • [1] RELATIONSHIP BETWEEN MTHFR POLYMORPHISM AND SIDE EFFECTS OF HIGH-DOSE METHOTREXATE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
    Ragab, S. M.
    El-Rashedy, F. H.
    Dawood, A. A.
    El-Hawy, M. A.
    HAEMATOLOGICA, 2014, 99 : 279 - 279
  • [2] Acute Myelitis That Developed in A Pediatric Patient With Acute Lymphoblastic Leukemia After High-Dose Methotrexate Therapy
    Matsumoto, Kazuki
    Yamashita, Daiki
    Zhu, Yiqing
    Sajiki, Daichi
    Maemura, Ryo
    Sakaguchi, Hirotoshi
    Yoshida, Nao
    Hama, Asahiko
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S29 - S30
  • [3] Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia
    Liu, Shu-Guang
    Gao, Chao
    Zhang, Rui-Dong
    Zhao, Xiao-Xi
    Cui, Lei
    Li, Wei-Jing
    Chen, Zhen-Ping
    Yue, Zhi-Xia
    Zhang, Yuan-Yuan
    Wu, Min-Yuan
    Wang, Jian-Xiang
    Li, Zhi-Gang
    Zheng, Hu-Yong
    ONCOTARGET, 2017, 8 (23) : 37761 - 37772
  • [4] Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: Relation to pharmacokinetic parameters of methotrexate
    Rask, C
    Albertioni, F
    Schroder, H
    Peterson, C
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1996, 13 (04) : 359 - 367
  • [5] Encephalopathy under systemic high-dose methotrexate therapy in acute lymphoblastic leukemia
    Eisberg, S
    Tillmann, W
    MONATSSCHRIFT KINDERHEILKUNDE, 2000, 148 (01) : 13 - 17
  • [6] ORAL MUCOSITIS AND SALIVARY METHOTREXATE CONCENTRATION IN INTERMEDIATE-DOSE METHOTREXATE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
    ISHII, E
    YAMADA, SI
    HIGUCHI, S
    HONJO, T
    IGARASHI, H
    KANEMITSU, S
    KAI, T
    UEDA, K
    MEDICAL AND PEDIATRIC ONCOLOGY, 1989, 17 (05): : 429 - 432
  • [7] Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia
    Gao, Xuan
    Qian, Xiao-Wen
    Zhu, Xiao-Hua
    Yu, Yi
    Miao, Hui
    Meng, Jian-Hua
    Jiang, Jun-Ye
    Wang, Hong-Sheng
    Zhai, Xiao-Wen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [8] The Association Between Plasma Methotrexate Concentration and Genetic Variant in High-dose Methotrexate Therapy for Childhood Acute Lymphoblastic Leukemia
    Tanaka, Yoichi
    Urayama, Kevin
    Mori, Makiko
    Hasegawa, Daisuke
    Akahane, Koshi
    Ota, Setsuo
    Koh, Katsuyoshi
    Manabe, Atsushi
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S97 - S98
  • [9] High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia
    Gokbuget, N
    Hoelzer, D
    ANNALS OF HEMATOLOGY, 1996, 72 (04) : 194 - 201
  • [10] The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia
    Liao, Chan
    Nie, Jing
    Xu, Xiao-Jun
    Zhang, Jing-Ying
    Xu, Wei-Qun
    Song, Hua
    Shen, He-Ping
    Shen, Di-Ying
    Zhao, Fen-Ying
    Liang, Juan
    Miao, Jing
    Tang, Yong-Min
    LEUKEMIA & LYMPHOMA, 2024, 65 (01) : 91 - 99